Janus kinase inhibitors in rheumatoid arthritis: Clinical applications

Australian Prescriber

Volumn 37, Issue 5, 2014, Pages 158-160

  Walker, Jennifer ^a   Smith, Malcolm ^a  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Molecular targeted therapy; Tofacitinib

Indexed keywords

ADALIMUMAB; CHOLESTEROL; CYTOCHROME P450 3A4; GLUCOCORTICOID; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CYTOPENIA; DIARRHEA; DISEASE ACTIVITY SCORE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEADACHE; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

EID: 84929863904     PISSN: 03128008     EISSN: 18393942     Source Type: Journal    
DOI: 10.18773/austprescr.2014.062     Document Type: Article

References (19)

1. O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii111-5.
2. Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013;9:753-61.
3. van Vollenhoven RF. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 2013;25:391-7.
4. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81.
5. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-8.
6. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP 690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29.
7. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
8. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
9. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al; ORAL Step Investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomized phase 3 trial. Lancet 2013;381:451-60.
10. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib (C-690,550) an oral Janus kinase inhibitor, in combination with traditional DMARDs: a phase 3 efficacy and safety study in patients with active rheumatoid arthritis with inadequate response to DMARDs [abstract]. Ann Rheum Dis 2011;70(Suppl 3):170.
11. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (C-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelvemonth data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
12. Lee EB, Fleischmann RM, Hall S, van Vollenhoven RF, Bradley J, Gruben D, et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naïve patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2012;64 Suppl 10:S2486.
13. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum 2014. DOI: 10.1002/art.38745.
14. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2014;73:871-2.
15. Cohen S, Krishnaswami S, Benda B, Riese R, Boy MG, Gruben D, et al. Tofacitinib, an oral Janus kinase inhibitor: analyses of efficacy and safety of 10 versus 5mg twice daily in a pooled phase 3 and long-term extension rheumatoid arthritis population [abstract]. Arthritis Rheum 2012;64 Suppl 10;2485.
16. McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomized study. Ann Rheum Dis 2014;73:124-31.
17. Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97.
18. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2013. doi:10.1111/jdv.12081. Epub ahead of print.
19. Vincenti F, Tedesco SH, Busque S, O’Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012;12:2446-56.